MOTS-c Half-Life

What is MOTS-c and why does its half-life matter?

MOTS-c is a small peptide encoded within mitochondrial DNA, and its half-life matters because clearance rate shapes how a compound behaves over time in research models. Lee et al., 2015 (Cell Metabolism) described MOTS-c as a 16-amino-acid mitochondrial-derived peptide that influences metabolic homeostasis, partly through activation of AMP-activated protein kinase (AMPK). That work established the molecule as a signaling peptide of interest in metabolic research. It did not set out to define a clinical dosing interval or a plasma half-life in humans.

Half-life, in pharmacokinetics, is the time it takes for the concentration of a substance in plasma to fall by half. It is one input researchers use to understand exposure over time. For MOTS-c specifically, that input has not been pinned down in a published human study.

Is there a published human half-life for MOTS-c?

No: as of this writing, there is no validated human half-life for MOTS-c in the peer-reviewed literature. The foundational MOTS-c paper by Lee et al., 2015 (Cell Metabolism) characterized the peptide's biology and signaling, not its clinical pharmacokinetics. Human trials with reported plasma clearance curves for MOTS-c have not been published in a form that supports a firm half-life figure.

This is a common situation with newer research peptides. Where a claim needs a source that does not exist, the honest answer is to say the data are limited rather than to quote a number that cannot be traced to a real study. Any half-life value circulating for MOTS-c that lacks a citation to a completed human pharmacokinetic trial should be read as an estimate or an extrapolation, not an established fact.

What can peptide pharmacokinetics tell us in the absence of MOTS-c-specific data?

General principles suggest short, unmodified peptides clear from plasma quickly, but this is an extrapolation and not a measured MOTS-c figure. Small linear peptides without chemical modifications (such as fatty-acid acylation or amino-acid substitutions that resist enzymatic breakdown) are typically susceptible to rapid degradation by peptidases and to renal filtration. Compare this with engineered long-acting peptides: CJC-1295, for example, was designed for sustained action, and Teichman et al., 2006 (Journal of Clinical Endocrinology and Metabolism) reported sustained growth hormone and IGF-1 responses tied to its modified structure. MOTS-c, as described by Lee et al., 2015 (Cell Metabolism), is a native 16-amino-acid sequence without such half-life-extending modifications.

The takeaway: absent a MOTS-c pharmacokinetic trial, the reasonable expectation is a short plasma residence, but the specific hours or minutes are not documented for this compound in humans.

How does MOTS-c compare to peptides with better-characterized kinetics?

Unlike several growth-hormone secretagogues and GLP-1-class agents, MOTS-c has no published human clearance profile, so comparisons are structural rather than numeric.

This grid is a comparison of evidence maturity, not a claim that these compounds are interchangeable. MOTS-c sits in the "biology described, kinetics not established" column.

Does route or formulation change what we can say about MOTS-c half-life?

Route and formulation can change exposure for any peptide, but for MOTS-c there is no published human dataset that lets us quantify those effects. In principle, unmodified peptides delivered by different routes show different absorption and clearance patterns, and formulation choices can alter stability. For MOTS-c specifically, Lee et al., 2015 (Cell Metabolism) worked in experimental models to characterize signaling, not to compare human dosing routes or to publish a clearance table. So while route almost certainly matters, the peer-reviewed record does not give MOTS-c-specific numbers to report here.

What should a reader do with dosing questions?

Route personal dosing questions to a qualified clinician, because this page reports what studies describe and does not prescribe anything. The published MOTS-c literature centers on mechanism (Lee et al., 2015, Cell Metabolism) and does not define human dosing schedules, intervals, or a validated half-life. Any decision about use belongs with a licensed medical professional who can weigh individual circumstances. Nothing here is a recommendation to take, inject, cycle, or stack any compound.